Bayer Healthcare Drug Patent Portfolio
Bayer Healthcare owns 3 orange book drugs protected by 29 US patents Given below is the list of Bayer Healthcare's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11168058 | Manufacture of a crystalline pharmaceutical product | 27 Feb, 2038 | Active |
| US10045991 | Methods of treating pediatric cancers | 04 Apr, 2037 | Active |
| US10137127 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | 04 Apr, 2037 | Active |
| US10668072 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | 04 Apr, 2037 | Active |
| US11191766 | Methods of treating pediatric cancers | 04 Apr, 2037 | Active |
| US11484535 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide | 04 Apr, 2037 | Active |
| US10799505 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | 15 Aug, 2036 | Active |
| US10010530 | Carboxamide derivative and its diastereomers in stable crystalline form | 28 Jan, 2036 | Active |
| US10383853 | Carboxamide derivative and its diastereomers in stable crystalline form | 28 Jan, 2036 | Active |
| US10835515 | Carboxamide derivative and its diastereomers in stable crystalline form | 28 Jan, 2036 | Active |
| US10172861 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | 16 Nov, 2035 | Active |
| US9782414 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | 16 Nov, 2035 | Active |
| US8975254 | Androgen receptor modulating compounds | 25 Mar, 2033 | Active |
| US10383876 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts | 29 Mar, 2032 | Active |
| US9636344 | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts | 29 Mar, 2032 | Active |
| US10711013 | Androgen receptor modulating compounds | 27 Oct, 2030 | Active |
| US11046713 | Androgen receptor modulating compounds | 27 Oct, 2030 | Active |
| US9657003 | Androgen receptor modulating compounds | 27 Oct, 2030 | Active |
| US8513263 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | 23 Dec, 2029 | Active |
| US8466283 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | 22 Oct, 2029 | Active |
| USRE46856 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | 22 Oct, 2029 | Active |
| US10005783 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | 21 Oct, 2029 | Active |
| US10047097 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | 21 Oct, 2029 | Active |
| US10774085 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | 21 Oct, 2029 | Active |
| US8865698 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | 21 Oct, 2029 | Active |
| US9127013 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | 21 Oct, 2029 | Active |
| US9447104 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | 21 Oct, 2029 | Active |
| US9676783 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | 21 Oct, 2029 | Active |
| US7511041 | Fused azole-pyrimidine derivatives | 13 May, 2024 | Expired |
Latest Legal Activities on Bayer Healthcare's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Bayer Healthcare.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Apr, 2024 | US10813936 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 27 Mar, 2024 | US10799505 |
| Letter from FDA or Dept of Agriculture re PTE application | 18 Mar, 2024 | US7511041 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Mar, 2024 | US9447104 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Feb, 2024 | US10774085 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 04 Jan, 2024 | US10711013 |
| Notice of Final Determination -Eligible | 07 Dec, 2023 | US7511041 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Nov, 2023 | US10668072 |
|
FDA Final Eligibility Letter
Critical
| 14 Nov, 2023 | US7511041 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 22 Feb, 2023 | US9127013 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Feb, 2023 | US10383853 |
|
Patent Term Extension Certificate
Critical
| 15 Feb, 2023 | US8975254 |
| transaction for FDA Determination of Regulatory Review Period | 14 Feb, 2023 | US7511041 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 Feb, 2023 | US10383876 |
| transaction for FDA Determination of Regulatory Review Period | 18 Jan, 2023 | US7511041 |
Bayer Healthcare Drug Patents' Oppositions Filed in EPO
Bayer Healthcare drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 17, 2023, by Hamm&Wittkopp Patentanwälte Partmbb. This opposition was filed on patent number EP16704029A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP16704029A | Feb, 2023 | Hamm&Wittkopp Patentanwälte PartmbB | Granted and Under Opposition |
Bayer Healthcare's Family Patents
Bayer Healthcare drugs have patent protection in a total of 56 countries. It's US patent count contributes only to 13.5% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Bayer Healthcare Drug List
Given below is the complete list of Bayer Healthcare's drugs and the patents protecting them.
1. Aliqopa
Aliqopa is protected by 5 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10383876 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
29 Mar, 2032
(7 years from now)
| Active |
| US9636344 | Substituted 2,3-dihydroimidazo[1,2-C]quinazoline salts |
29 Mar, 2032
(7 years from now)
| Active |
| US8466283 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
22 Oct, 2029
(4 years from now)
| Active |
| USRE46856 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
22 Oct, 2029
(4 years from now)
| Active |
| US7511041 | Fused azole-pyrimidine derivatives |
13 May, 2024
(6 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aliqopa's drug page
2. Nubeqa
Nubeqa is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11168058 | Manufacture of a crystalline pharmaceutical product |
27 Feb, 2038
(13 years from now)
| Active |
| US10010530 | Carboxamide derivative and its diastereomers in stable crystalline form |
28 Jan, 2036
(11 years from now)
| Active |
| US10383853 | Carboxamide derivative and its diastereomers in stable crystalline form |
28 Jan, 2036
(11 years from now)
| Active |
| US10835515 | Carboxamide derivative and its diastereomers in stable crystalline form |
28 Jan, 2036
(11 years from now)
| Active |
| US8975254 | Androgen receptor modulating compounds |
25 Mar, 2033
(8 years from now)
| Active |
| US10711013 | Androgen receptor modulating compounds |
27 Oct, 2030
(5 years from now)
| Active |
| US11046713 | Androgen receptor modulating compounds |
27 Oct, 2030
(5 years from now)
| Active |
| US9657003 | Androgen receptor modulating compounds |
27 Oct, 2030
(5 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Nubeqa's drug page
3. Vitrakvi
Vitrakvi is protected by 16 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10045991 | Methods of treating pediatric cancers |
04 Apr, 2037
(12 years from now)
| Active |
| US10137127 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
04 Apr, 2037
(12 years from now)
| Active |
| US10668072 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
04 Apr, 2037
(12 years from now)
| Active |
| US11191766 | Methods of treating pediatric cancers |
04 Apr, 2037
(12 years from now)
| Active |
| US11484535 | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
04 Apr, 2037
(12 years from now)
| Active |
| US10799505 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
15 Aug, 2036
(11 years from now)
| Active |
| US10172861 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
16 Nov, 2035
(11 years from now)
| Active |
| US9782414 | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
16 Nov, 2035
(11 years from now)
| Active |
| US8513263 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
23 Dec, 2029
(5 years from now)
| Active |
| US10005783 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
21 Oct, 2029
(4 years from now)
| Active |
| US10047097 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
21 Oct, 2029
(4 years from now)
| Active |
| US10774085 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
21 Oct, 2029
(4 years from now)
| Active |
| US8865698 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
21 Oct, 2029
(4 years from now)
| Active |
| US9127013 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
21 Oct, 2029
(4 years from now)
| Active |
| US9447104 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
21 Oct, 2029
(4 years from now)
| Active |
| US9676783 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
21 Oct, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vitrakvi's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List